Love the news in the report (hidden again) - key words "ramp materially" for Continuous Glucose Monitor in late FY21 and key words again "material agreement" for NanoDX once FDA approval.
Pipeline:
Continuous Glucose Monitor FY21
NanoDX
Laser-Based Sensor FY22
Additionally within report I like the board comments "Based on its assessment of the cashflow projections over the ensuing 12 months from the date of this report, the Board is satisfied that sufficient funds are available for the Group to pay its debts as and when they fall due for at least the next 12 months from the date of this report"
My own opinions / thoughts do your own research.
- Forums
- ASX - By Stock
- SE1
- Ann: Half Year Accounts - Appendix 4D
Ann: Half Year Accounts - Appendix 4D, page-8
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)